Q4 2025 Microbix Biosystems Inc Earnings Call Transcript
Key Points
- Microbix Biosystems Inc (MBXBF) maintained a strong cash balance of over $12 million at the end of fiscal 2025, providing financial stability.
- The company has made significant investments in capital equipment and facilities, positioning itself for future growth.
- Operational improvements have led to increased batch yields and reduced failure rates, enhancing efficiency and margins.
- Microbix Biosystems Inc (MBXBF) has expanded its product offerings, including the launch of the QUANTDx reference materials product line.
- The company has strengthened its supply chain with an exclusive agreement with the Bulgarian National Center for Infectious and Parasitic Diseases.
- Revenues for fiscal 2025 were down 27% compared to the previous year, impacted by the loss of major clients and reduced sales in China.
- The company experienced a significant decline in gross margins, dropping from 61% to 53% year-over-year.
- There was a notable increase in operating expenses, up 4%, due to lower investment income and increased R&D spending.
- Microbix Biosystems Inc (MBXBF) faced a cybersecurity incident, although it did not disrupt operations, it required additional resources for mitigation.
- The company anticipates a reduction in cash reserves through fiscal 2026 as it works towards regaining profitability.
Good morning, everyone. Thanks for joining us today. We have Microbix here to talk about their Q4 and Year-End Results for 2025. Before we get into those, I don't believe we're going to work off our presentation today, but I'd like to remind you that this session, as always, will contain forward-looking statements. If you'd like to know more about those, you can find them on the company's website in the presentation.
There's disclosures there. I believe the format will be an update from the team on the Q4 and year-end results, and then we'll jump into Q&A. (Operator Instructions) And with that out of the way, I'd like to introduce Cameron Groome, President and CEO; Ken Hughes, COO; and Jim Currie, CFO. Hi, gentlemen, thanks for joining me today.
Thank you very much, Deborah. That's brilliant. Much appreciate the help as always.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
